PALISADE BIO, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $250,000 | $0 | — |
| Operating income | -$18.1M | -$14.9M | -$13.1M | -$15.7M | -$41.9M |
| Operating expenses | $18.1M | $14.9M | $13.3M | $15.7M | $41.9M |
| Cash from operations | -$10.8M | -$12.2M | -$11.1M | -$13.4M | -$14.8M |
| Capital expenditure | — | $0 | $4,000 | $10,000 | $0 |
| Free cash flow | — | -$12.2M | -$11.1M | -$13.4M | -$14.8M |
| Total assets | $134.3M | $10.9M | $14.1M | $15.8M | $12.5M |
| Total liabilities | $5.0M | $3.4M | $2.7M | $3.3M | $5.1M |
| Total debt | — | — | — | — | $87,000 |
Shares outstanding 173.6M · Free float 84.7%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.